杨学欣,孙璐,徐静静,宋楠楠,路橦,李乐道,李晨旭
YANG Xuexin,SUN Lu,XU Jingjing,SONG Nannan,LU Tong,LI Ledao,LI Chenxu

• 1:沈阳药科大学药学院

摘要(Abstract)：

目的建立快速灵敏的超高效液相色谱-质谱联用(UPLC-MS)法,研究Beagle犬分别以9.6、19.2、28.8 mg·kg-1的剂量经口给药盐酸丁咯地尔后,丁咯地尔及主要代谢物O-去甲基丁咯地尔在健康Beagle犬体内的药物代谢动力学行为。方法采用甲醇沉淀蛋白法进行血浆样品预处理,Acquity UPLC BEH C18(50 mm×2.1 mm,1.7μm)色谱柱,甲醇-5 mmol·L~(-1)醋酸铵(含体积分数为0.05%的甲酸)为流动相,梯度洗脱。采用ESI源正离子模式对血浆样品中丁咯地尔及其代谢物进行浓度检测,计算药代动力学参数。结果血浆中丁咯地尔和O-去甲基丁咯地尔的质量浓度分别在20.0~4 000.0μg·L~(-1)和2.0~400.0μg·L~(-1)内线性关系良好,日内、日间精密度RSD均不超过10.4%,提取回收率为90.4%~96.3%,基质效应为93.2%~97.0%。丁咯地尔及O-去甲基丁咯地尔血浆样品在所考察的储存条件下均可保持稳定。结论该方法适用于丁咯地尔及O-去甲基丁咯地尔在Beagle犬体内的药物代谢动力学研究。Beagle犬给药9.6~28.8 mg·kg-1剂量内,丁咯地尔药物代谢动力学行为呈线性关系,O-去甲基丁咯地尔药动学行为呈非线性关系。
Objective To establish a rapid and sensitive ultra-performance liquid chromatography-mass spectrometry(UPLC-MS) method for the simultaneously determine buflomedil and its major metabolite Odesmethylbuflomedil in dog plasma after oral administration of buflomedil hydrochloride at doses of 9. 6,19. 2 and 28. 8 mg ·kg-1,respectively,and apply the method to study the pharmacokinetics of buflomedil and O-desmethylbuflomedil in Beagle dogs. Methods The plasma samples were pretreated by protein precipitation with methanol,and chromatographic separation was performed on an Acquity UPLC BEH C18 column using a gradient elution with mobile phase consisting of methanol and 5 mmol·L~(-1) NH4 AC containing 0. 05% formic acid. The detection was carried out by Waters XevoTMG2 QTOF equipped with electrospray ionization source in positive ion mode. Results The method was linear over the range of 20. 0-4 000. 0 μg·L~(-1) for buflomedil and 2. 0-400. 0 μg·L~(-1) for O-desmethylbuflomedil,and the intra-day and inter-day precision were below10. 4%. The extraction recovery were ranged from 90. 4% to 96. 3%,and the matrix effect were ranged from 93. 2% to 97. 0%. The plasma samples of the two analytes were found to be stable in the different conditions investigated in this article. Conclusions The method was successfully applied in the pharmacokinetic study of buflomedil and O-desmethylbuflomedil in dog plasma. The pharmacokinetics of buflomedil was linear in the dose range of 9. 6-28. 8 mg·kg-1 in Beagle dogs,while the pharmacokinetic behavior of O-demethylbuflomedil showed a nonlinear relationship during the same dose.

关键词(KeyWords)： 丁咯地尔;O-去甲基丁咯地尔;超高效液相色谱-质谱联用法;药物动力学
buflomedil;O-desmethylbuflomedil;ultra-performance liquid chromatography with tandem mass spectrometry;pharmacokinetics

Abstract:

Keywords:

基金项目(Foundation): 辽宁省教育厅项目(L2014390);; 沈阳药科大学中青年教师中长期培养计划(ZQN2015007);; 国家大学生创新创业训练计划项目(201710163000217)

作者(Author): 杨学欣,孙璐,徐静静,宋楠楠,路橦,李乐道,李晨旭
YANG Xuexin,SUN Lu,XU Jingjing,SONG Nannan,LU Tong,LI Ledao,LI Chenxu

DOI: 10.14066/j.cnki.cn21-1349/r.2018.03.009

参考文献(References)：

• [1]张文.试析盐酸丁咯地尔的药理作用研究与临床应用[J].中国中医药咨讯,2009,1(4):89-89.
• [2]裴大勇.丁咯地尔用于慢性脑供血不足的临床治疗分析[J].中国医药指南,2016,14(13):145.
• [3]BUCOLO C,LONGO L,CAMILLIERI G,et al.Safety profile assessment of buflomedil:an overview of adverse reactions between 1975 and 2011[J].Pharmacoepidemiology and Drug Safety,2012,21:1190-1196.
• [4]ALBERTI A,VALENTI S,GALLO F,et al.Acute buflomedil intoxication:a life-threatening condition[J].Intensive Care Med,1994,20(1):219-221.
• [5]郭少华,李成建,余彩明.丁咯地尔不良反应[J].中国误诊学杂志,2010,10(3):733.
• [6]赵桂宏.欧洲停止使用丁咯地尔口服制剂[J].药物不良反应杂志,2011,13(3):204.
• [7]国家食品药品监督管理局.国家食品药品监督管理局关于停止生产销售使用丁咯地尔的通知[EB/OL].[2013-3-5]http://www.sfda.gov.cn/WS01/CL0844/79101.html.
• [8]BHATTACHARYA S S,BANERJEE S.Skin permeation of buflomedil form adhesive matrix patches[J].Journal of Adhesion Science and Technology,2015,29(10):925-942.
• [9]GUNDERT R,WEBER E,LAM G,et al.The clincal pharmacokinetics of buflomedil in normal subjects after intravenous and oral administration[J].European Journal of Clinical Pharmacology,1981,20(1):459-463.
• [10]THOMAS E W.Analysis of buflomedil in mouse,rat and rabbit plasma by reversed-phase ion-pair high-performance liquid chromatography[J].Journal of Chromatography,1982,228(1):387-391.
• [11]FORFAR B I,PEHOURCQ F,JARRY C.Rapid HPLC measurement of buflomedil in plasma in poisoning cases[J].Biomedical Chromatography,2002,16:482-485.
• [12]MARAO A.Gas chromatographic evaluation of buflomedil in biological samples employing the thermoionic specific detector[J].Journal of Chromatography,1988,417(1):345-350.
• [13]LI R,CHUN Y,YAN P,et al.Application of a high performance liquid chromatography-tandem mass spectrometry method for determination of buflomedil in human plasma for a bioequivalence study[J].Journal of Chromatography B,2013,935:41-46.
• [14]钟大放.以加权最小二乘法建立分析标准曲线的若干问题[J].药物分析杂志,1996,16(5):343-346.
• [15]杨亚楠.盐酸丁咯地尔的人体生物等效性和药物代谢研究[D].沈阳:沈阳药科大学,2011.
• [16]谢菡,阿罗那,葛卫红.曲马多代谢相关基因多态性研究进展[J].现代生物医学进展,2015,15(19):3797-3800.
• [17]韩璐,刘杰.CYP2D6基因多态性及对药物代谢的影响[J].中国临床药理学与治疗学,2011,16(1):105-110.
• [18]WANG D X,AUDREY G,SUN X C.Functional characterization of CYP2D6 enhancer polymorphisms[J].Human Molecular Genetics,2015,24(6):1556-1562.